Abstract:As seen in this CME online activity (available at http://courses.elseviercme.com/694), idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrotic lung disease of unknown cause that is associated with substantial health-care utilization and high rates of mortality. The clinical symptoms of IPF are nonspecific and overlap with many pulmonary and cardiac diseases making differential diagnosis challenging. The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines strongly recommend a multidisciplinary approach to the diagnosis of interstitial lung diseases; however, there are several limitations to the feasibility of this approach in clinical practice. Although early diagnosis is relevant to any chronic, progressive, and irreversible disorder, it is crucially important that effective treatments for IPF are prescribed without delay. A window of opportunity may exist during which time treatment can have optimal outcomes. Evidence on the clinical management of IPF is rapidly evolving, and key updates were made to the most recent ATS/ERS/JRS/ALAT guidelines. The widely used combination of prednisone, azathioprine, and N-acetylcysteine has now been associated with increased risk of hospitalization and death compared with placebo in patients with IPF. These treatments and others for IPF have been mostly supportive, but recently pirfenidone and nintedanib have demonstrated efficacy in reducing functional decline and disease progression in IPF. A pooled analysis of three phase 3 studies of pirfenidone found a significant 48% reduction in all-cause mortality, and a pooled analysis of a phase 2 and two phase 3 studies of nintedanib found a significant 43% reduction in on-treatment mortality. As patient exposure to these two new drugs increases, data continue to emerge on how and when to use these medications and on how to manage their side effects. Finally, several medications targeting the fibrotic pathobiology of IPF are currently in development. Given the limited treatment options for IPF, enrollment in a clinical trial may be the best chance to delay or prevent progression of IPF. This CME-certified expert video roundtable from CHEST reviews the ATS/ERS/JRS/ALAT guidelines with a specific focus on accurate and timely diagnosis of IPF and the latest data on the treatment of IPF.

Further investigations on transcription and translation in Limnaea embryos.

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry

Gastroesophageal reflux disease and idiopathic pulmonary fibrosis risk: A mendelian randomization study

Managing Cough in Idiopathic Pulmonary Fibrosis

The mechanism of gut-lung axis in pulmonary fibrosis

[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]

Idiopathic pulmonary fibrosis: state of the art for 2023

[Hypothalamic control of thyroid function].

Idiopathic Pulmonary Fibrosis: Review of Current Knowledge

Forecasting TAIFEX based on fuzzy time series and particle swarm optimization

Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment

Cardiac Troponin T and NT-proBNP as Biomarkers of Early Myocardial Damage in Amitriptyline-Induced Cardiovascular Toxicity in Rats

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis

Changes in chicken intestinal zinc exporter mRNA expression and small intestinal functionality following intra-amniotic zinc-methionine administration.

Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study

Idiopathic Pulmonary Fibrosis (IPF): An Overview

Idiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review

Cerebral venous thrombosis in children.

[Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances]

Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments